CanSino Biologics Inc
06185
Company Profile
Business description
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.
Contact
185 South Avenue
401-420, 4th Floor, Biomedical Park
TEDA West District
Tianjin
CHNT: +86 4009222099
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,105
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,834.00 | 88.40 | 1.01% |
| CAC 40 | 8,000.92 | 47.15 | 0.59% |
| DAX 40 | 23,353.54 | 190.62 | 0.82% |
| Dow JONES (US) | 46,138.77 | 47.03 | 0.10% |
| FTSE 100 | 9,550.76 | 43.35 | 0.46% |
| HKSE | 25,835.57 | 4.92 | 0.02% |
| NASDAQ | 22,564.23 | 131.38 | 0.59% |
| Nikkei 225 | 49,823.94 | 1,286.24 | 2.65% |
| NZX 50 Index | 13,439.40 | 112.50 | 0.84% |
| S&P 500 | 6,642.16 | 24.84 | 0.38% |
| S&P/ASX 200 | 8,552.70 | 84.70 | 1.00% |
| SSE Composite Index | 3,931.05 | 15.69 | -0.40% |